Bank of America started coverage on shares of Legend Biotech (NASDAQ:AMTI) in a research report released on Tuesday, BenzingaRatingsTable reports. The firm issued a buy rating and a $34.00 price objective on the stock.
AMTI stock opened at $27.00 on Tuesday. Legend Biotech has a 52 week low of $17.05 and a 52 week high of $31.84.
About Legend Biotech
See Also: Accumulation/Distribution
Receive News & Ratings for Legend Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Legend Biotech and related companies with MarketBeat.com's FREE daily email newsletter.